Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175503 | 0.84 | GRM4 (0.72) | GRM4SMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL28764679 | 0.84 | L3MBTL1 (0.66) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL29837506 | 0.84 | L3MBTL1 (0.66) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL4283746 | 0.83 | NPC1 (0.57) | GRM4SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL6772756 | 0.83 | GRM5 (0.62) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL6769262 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL5205251 | 0.80 | L3MBTL1 (0.57) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL30338953 | 0.80 | NPC1 (0.70) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL890674 | 0.80 | NPC1 (0.70) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 | |
| SCHEMBL18070988 | 0.80 | L3MBTL1 (0.60) | SMN1; SMN2L3MBTL1BRD4RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| CN-100475777-C | Amide type carboxamide derivative | TANABE SEIYAKU CO (JP) | 2009-04-08 | — | — | CN | disclosed |
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7375119-B2 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20040058959-A1 | Substituted carboxamides | HERRON DAVID KENT (US) | 2004-03-25 | — | — | US | disclosed |
| US-6689780-B1 | PYRIDINE DERIVATIVES | ELI LILLY AND COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1379506-A2 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1140905-B1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1307444-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002064567-A2 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002010154-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1140905-A1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039117-A1 | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | GRM4 4725/4885SMN1; SMN2 4162/4885L3MBTL1 4258/4885 |
| US-20040058959-A1 | Substituted carboxamides | F11, F12, TFPI | GRM4 4592/4885SMN1; SMN2 2880/4885L3MBTL1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.